Dr. Jilg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Massachusetts General Hospital
55 Fruit St
Boston, MA 02114Phone+1 617-726-2061
Summary
- Dr. Nikolaus Jilg is an Internal Medicine specialist based in Boston, MA, with a subspecialty in Infectious Disease. He completed his fellowship in Infectious Disease at Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical School (2016-2018) following his Internal Medicine Residency also at Massachusetts General Hospital (2013-2016). Dr. Jilg is a Clinical Fellow at Mass General Brigham. His research is widely published in recognized journals such as The Journal of Infectious Diseases, Eclinicalmedicine, and the Journal of Clinical and Translational Science. His work focuses primarily on SARS-CoV-2, COVID-19, and related therapeutics.
Education & Training
Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 2016 - 2018- Massachusetts General HospitalResidency, Internal Medicine, 2013 - 2016
Certifications & Licensure
MA State Medical License 2013 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Publications & Presentations
PubMed
- SARS-CoV-2 Plasma Antibody and Nucleocapsid Antigen Status Predict Outcomes in Outpatients With COVID-19.Nikolaus Jilg, Mark J Giganti, Kara W Chew, Katy Shaw-Saliba, Justin Ritz
Clinical Infectious Diseases. 2024-10-15 - 2 citationsSARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir.Kanal Singh, Kevin Rubenstein, Viviane Callier, Katy Shaw-Saliba, Adam Rupert
The Journal of Infectious Diseases. 2024-09-23 - Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial.Teresa H Evering, Carlee Moser, Nikolaus Jilg, Justin Ritz, David A Wohl
Eclinicalmedicine. 2024-09-01
Press Mentions
ACTG Adds Four Promising New Therapies to ACTIV-2 Outpatient Treatment StudyFebruary 12th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
